Company Listing
Algeta

Algeta developed novel targeted cancer therapies based on its alpha-pharmaceutical platform. The company’s lead product, Xofigo®, is approved in the US and Europe for skeletal metastases from prostate cancer. Algeta was Abingworth’s first VIPE (Venture Investment in Public Equity) and was acquired by Bayer for $2.9 billion in March 2014.

BACK
Location
Oslo, Norway

Home

About Us

  1. About Us
  2. Our Team
  3. Transatlantic Reach
  4. Funds

Strategy

  1. Our Strategy
  2. Venture Capital
  3. Clinical Co‑development
  4. VIPEs
  5. Public Markets

Portfolio

  1. Portfolio Companies
  2. Case Studies

Media Centre

  1. Recent News
  2. Archived News
  3. Film

Contact

  1. Contact Us
  2. Send Us Your Proposal
Company Listing

Algeta developed novel targeted cancer therapies based on its alpha-pharmaceutical platform. The company’s lead product, Xofigo®, is approved in the US and Europe for skeletal metastases from prostate cancer. Algeta was Abingworth’s first VIPE (Venture Investment in Public Equity) and was acquired by Bayer for $2.9 billion in March 2014.

Location
Oslo, Norway
BACK
 
Copyright Abingworth 2017